SPX3,693.23-64.76 -1.72%
DIA295.86-4.66 -1.55%
IXIC10,867.93-198.88 -1.80%

NGM Bio Presents Updated Preliminary Findings From Ongoing Phase 1b Dose Escalation Trial Of NGM120 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Cancer At AACR Special Conference: Pancreatic Cancer

NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 +

Benzinga · 09/13/2022 17:32
  • NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer
  • NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 + gemcitabine + Nab-paclitaxel) with no dose-limiting toxicities
  • As of the March 15, 2022 abstract data cut-off date, among the six evaluable patients in the Phase 1b combination cohort, a disease control rate of 100% was observed, median progression-free survival had not been reached and the 12-month survival rate was 83.3%
    • Three of the six evaluable patients experienced partial responses (PR) extending more than 32 weeks as of the abstract cut-off date, including one patient with a PR that was ongoing at 90 weeks as of August 15, 2022